PolTREG S.A. is currently at various stages of clinical research and development (therapy of type 1 diabetes in children, and multiple sclerosis) using T-regulatory cells (TREGS). The company’s strategy assumes the development of a platform for therapies based on the use of TREGS in the treatment of autoimmune diseases and achieving the position of one of the leaders of such therapies in the world.
The Company submitted at the end of June, to the Polish Financial Supervision Commission (in PL: KNF) prospectus in connection with the intention to carry out an initial public offering (IPO), and admission and introduction of shares to trading on the regulated market of the Warsaw Stock Exchange in Warsaw S.A. (in PL: GPW).
PolTREG plans to debut on the stock exchange in the fourth quarter of 2021. The funds that the Company intends to obtain from the public offering (IPO) shall be used to finance the current research and development projects related to the next stages of clinical trials on the treatment of type 1 diabetes in children and the treatment of multiple sclerosis.


Press publications: